Published in Biotech Law Weekly, February 23rd, 2007
The terms grant Quest Diagnostics rights to develop an advanced screening method for FXS based on Quest Diagnostics' and U.S. Genomics' jointly developed genetic testing technology. Additional terms of the agreement were not disclosed. Approximately one in 1,500 males and one in 4,000 to 6,000 females worldwide are born with FXS.
Using U.S. Genomics' applications, Quest Diagnostics plans...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.